CF PharmTech, Inc. disclosed a share repurchase on 23 April 2026, executing its mandate approved on 16 December 2025.

Key transaction details • Shares repurchased: 16,500 ordinary H-shares, acquired on the Hong Kong Stock Exchange. • Price range: HKD 20.90–21.34 per share; volume-weighted average price: HKD 21.10. • Cash outlay: HKD 348,200 (approximately 0.35 million).

Impact on share capital • Issued shares (excluding treasury) fell to 301.61 million from 301.63 million. • Treasury shares increased to 613,000, bringing total issued shares (including treasury) to 302.22 million, unchanged from the prior day.

Repurchase mandate utilisation • Authorised capacity: 30.22 million shares. • Cumulative repurchases since the mandate: 613,000 shares, equivalent to 0.20 % of the issued share base on the mandate date.

Regulatory window Under Main Board Rule 10.06(3)(a), the company is restricted from issuing new shares or disposing of treasury shares until 23 May 2026, 30 days after the latest buyback.

The board confirmed that all repurchase procedures complied with Hong Kong listing rules and relevant regulations.